Clinical Trial Update: Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the investigational combination of daratumumab and teclistamab versus standard regimens in high-risk relapsed or refractory mul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING